Since there is a tendency to early brain metastasis in early stage patients with high-grade, lobular/mixed type histology tumors and with a high number of involved lymph nodes, the value of PCI can be explored in these patients by a well designed prospective trial. Advanced stage chemosensitive patients with ErbB-2 over-expression and/or with hepatic metastasis at their first relapse may be candidates for PCI. There is no place for PCI in chemoresistant and triple-negative breast cancer patients.

No abstract

Purpose Many studies report the triple negative breast cancer (TNBC) as the worst subgroup, as such patients do not benefit from anti-hormonal therapy and human epidermal growth factor receptor 2 (HER2) antagonists. While HER2 overexpression was a poor prognostic factor in breast cancer before trastuzumab (Herceptin) was available, TNBC is often reported as the worst BC subgroup since targeted therapy is currently not possible. Since the patience-specific experiences and the current literature did not always align, we aimed to determine the BC subgroup with the shortest survival in our center. Methods The records of patients with BC who were admitted to Trakya University Faculty of Medicine Department of Medical and Radiation Oncology between July 1999 and December 2019 were reviewed. Patients were divided into four main groups (Luminal A, Luminal B, TNBC, and HER2-enriched) according to the St Gallen International Consensus Panel and four subgroups in accordance with estrogen receptor, progestin receptor and HER2 positivity. Patient characteristics, treatment characteristics and clinical outcomes of the four main subgroups were evaluated. Survival curves were generated using the Kaplan–Meier method, and the significance of survival differences among the selected variables was compared by using the Log rank test. Factors affecting disease-free survival (DFS) and overall survival (OS) were analyzed by Cox regression analysis. Results Statistical analysis was performed on 2017 patients, after excluding patients with phyllodes tumor, carcinoma-in-situ and missing information from a total of 2474 patients with BC. There were 952 (47.1%) patients in the Luminal A group, 236 (34.1%) in the Luminal B group, 236 (11.7%) in the TNBC group and 142 (7.1%) patients in the HER2 enriched group. HER2-enriched patients had the shortest survival (p < 0.001), with 113.70 ± 7.17 months of DFS and 125.45 ± 3.03 months of OS. For patients who received Herceptin, DFS was 101.50 ± 6.4 months and OS was 118.14 ± 6.16. Patients who did not receive Herceptin had 92.79 ± 18 months of DFS and 94.44 ± 15.23 months of OS. Conclusion The HER2-enriched subgroup had the worst prognosis despite receiving targeted therapy. While the duration of DFS and OS had no significant difference between TNBC and Luminal A-B subgroups, HER2 enriched subgroup had significantly shorter survival when compared to any other subgroup. HER2-enriched subgroup had a 10-fold greater risk of death compared to the Luminal A subgroup.

Angiosarcoma is a rare malignant tumour of endothelial cells. Primary angiosarcoma of venous origin is extremely rare, and has a very poor prognosis. A 63-year-old woman with retroperitoneal mass underwent en bloc resection on a part of iliac vein followed by adjuvant radiotherapy. No recurrence was detected during 3 years of follow-up.

1858he role of brachytherapy as a component of curative radiotherapy in patients with cervical cancer is well established.1, 2 The main purpose of the intracavitary treatment to deliver a curative dose to the priThe Effect of Positional Movement of a Semiflexible Applicator on Dose Distrubutions in Low Dose Rate Brachytherapy for Cervical Carcinoma A AB BS S T TR RA AC CT T O Ob bj je ec ct ti iv ve e: : Current study aims to detect the movements of a semiflexible applicator (TÖRE's applicator) in the first 24 hours and to analyze its effect on the calculated point A, bladder and rectum doses in low dose rate brachytherapy (LDR-BT) applications. M Ma at te er ri ia al l a an nd d M Me et th ho od ds s: : Eighty films were evaluated on 18 cervical carcinoma patients (20 applications) who were treated with curative radiotherapy. The comparison of the reference points and doses at critical organs were performed by using a reference axis which was fixed to bony landmarks in the pelvis. To evaluate the movement of the applicator, distance of the upper point and lower point of the tandem to the reference axis were measured. Additionally, the angular deviation of the applicator was tested. R Re e--s su ul lt ts s: : The movements of the upper point and lower point of the tandem in x, y, z axes were 5.30 ± 6.33 mm, 2.80 ± 2.24 mm, 6.65 ± 8.33 mm and 3.45 ± 4.32 mm, 3.75 ± 3.59 mm, 3.05 ± 3.08 mm, respectively. The mean differences were 3.30 ± 2.99º in α-angle and 5.65 ± 4.76º in β-angle. The mean percent dose changes in point A, bladder and rectum were 1.5±1.2%, 3.7±3.1%, 4.4±4.0%, respectively. C Co on nc cl lu us si io on n: : Our study demonstrates that there are some movements of the applicator during LDR-BT, however these movements do not result in significant dose changes in target volumes and critical organs. Therefore, positional correction is not required. In conclusion, CT-compatible TÖRE's applicator that allows an advantage for CT-based 3D planning is useful and safe for brachytherapy. K Ke ey y W Wo or rd ds s: : Brachytherapy; uterine cervical neoplasms Ö ÖZ ZE ET T A Am ma aç ç: : Çalışmamızın amacı, düşük doz brakiterapi (DDB) uygulamasındaki yarı-oynar aplikatörün ilk 24 saatteki hareketlerini taramak ve ölçümü yapılan A noktası, mesane ve rektumdaki etkilerini analiz etmektir. G Ge er re eç ç v ve e Y Yö ön nt te em ml le er r: : Küratif radyoterapi alan 18 serviks karsinomu hastasında (20 uygulama) 80 film değerlendirildi. Referans noktalarının ve kritik organlardaki dozların karşılatırılması, pelviste kemik üzerinde merkez alınmış referans ekseni kullanılarak gerçekleştirilmiştir. Aplikatörün hareketini değerlendirmede ise referans eksenine bire bir uzaklıktaki en üst ve en alt noktalar arasındaki mesafe ölçülmüştür. Aplikatörün açısal sapması da ayrıca test edilmiştir. B Bu ul lg gu ul la ar r: : Hareketlerin x, y ve z eksenine bire bir uzaklıktaki en üst ve en alt noktadaki ölçümleri sırasıyla 5.30 ± 6.33 mm, 2.80 ± 2.24 mm, 6.65 ± 8.33 mm and 3.45 ± 4.32 mm, 3.75 ± 3.59 mm, 3.05 ± 3.08 mm bulunmuş...

ÖZETAmaç: Lokal ileri evre meme kanserinde neoadjuvan kemoterapi ile hastalar meme koruyucu cerrahi olma şansını yakalayabilmektedir. Bu yazıda lokal ileri evre meme kanseri nedeni neoadjuvan kemoterapi sonrası meme koruyucu cerrahi,aksiler diseksiyon ve sentinel lenf nodu örneklemesi yapılmış hastaların sonuçları değerlendirilmiştir. Gereç ve Yöntemler:Bu çalışmaya 2002-2009 yılları arasında evre IIIA ve IIIB lokal ileri evre meme kanserli 12 hasta alınmıştır. Hastalara cerrahi öncesi antrasiklin bazlı kemoterapi rejimleri uygulanmıştır. Level 2 aksiller lenf nodu diseksiyonu öncesi sentinel lenf nodu örneklemesi, meme koruyucu cerrahi ve sonrasında radyoterapi yapılmıştır. Bulgular:Hastaların beşi evre IIIA, altısı IIIB ve biri evre IIIB idi.Hastalara 3-6 kür arası FAC/FEC rejimleri uygulandı. 8 hastada kısmi, 4'ünde tam yanıt alındı. Aksiller diseksiyon yapılan hastaların 5'inde pozitif lenf nodu görüldü. Lenf nodu ortanca değeri 12 (n:8-19) idi. Beş hastaya sentinel lenf nodu örneklemesi yapıldı.Bir hastada sentinel lenf nodu görüntüle-nemedi. Diseke edilen sentinel lenf nodu ortanca değeri 3,5 (n:3-4) idi. Hiçbir hastada lokoregional nüks görülmedi. Hastaların ortalama takip sü-resi 29.8 ay olup, ortanca takip süresi 16 (2-80) ay olarak tespit edildi. 12 hastanın 10'u yaşamakta olup 2'si exitus oldu.Sonuç: Uygun hastalarda multidisipliner çalışma ile neoadjuvan kemoterapi sonrası lokal ileri evre meme kanserlerinde meme koruyucu cerrahi ve sentinel lenf nodu yapılabilinir ve erken evre meme kanserinde olduğu gibi kür sansı sağlanabilir.Anahtar Sözcükler: Meme kanseri, lokal ileri evre, meme koruyucu cerrahi, sentinel lenf nodu örneklemesi Results: There were fi ve patients in stage IIIA, six in stage IIIB, and one in stage IIIC. Patients had received 3-6 regimen of FAC/FEC. Eight had partial and four had complete response. Five positive axilla were detected. The median value of the lymph nodes was 12 (n:8-19). Five patients underwent sentinel lymph node biopsy. The biopsy has failed in one patient and the median value of dissected sentinel node was 3.5 (n:3-4). Locoregional recurrence was not observed in any patients. The mean follow-up of the patients was 29.8 months and median time was 16 (n:2-80) months. Of the 12 patients 10 are alive and 2 were deceased. Conclusion:In selected locally advanced patients, breast conserving surgery and sentinel lymph node biopsy may be applied by a multidisciplinary approach, and excellent success may be achieved in those patients as in early breast cancer patients. GirişMeme kanseri kadınlarda en sık görülen malignitedir. Akciğer kanserinden sonra kansere bağlı ölümlerde ikinci sırayı oluşturmaktadır. Meme kanserinin tedavi stratejisi hastalığın evresine göre değişmektedir. Cerrahi branşların her dalında olduğu gibi minimal invazif ameliyat tekniklerine yönelim meme kanserinin cerrahi tedavisinde de radikal mastektomiden meme koruyucu cerrahiye doğru kaymaktadır (1). Lokal ileri evre meme kanseri (LİEMK) tüm meme kanserlerinin ortalama %20-25'ini oluşturmaktadır. Geniş ...

Radiation-induced acute and chronic lung toxicity is one of the important adverse events that has a negative influence on quality of life. It is widely accepted today that there are important factors such as personal sensibility and genetic differences between patients which effect both treatment response and treatment toxicity. In this study, the influence of gender differences on acute lung toxicity due to radiotherapy is investigated. Accordingly, it is examined if there is a relation between gender and histopathologically proven vasculitis and pneumonia in the lung tissues of male and female rats that are sacrificed 6 weeks after radiotherapy. It is concluded that the gender differences in rats have no effect on lung toxicity. Citation: Bilal BU, Kocak Z, Cosar R, Altaner S, Kocak M (2014) Histopathological investigation of differences between female and male rats on radiation-induced acute lung toxicity. J Cancer Res Ther 2: 84-88.

No abstract